APO RESEARCH · REPORT
NK Cell Therapy
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
Product & engineering
Understand the product.
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
Selected research
Industry Research
NK Cell Therapy Industry Research Report 2026
Market perspective
Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
North America is the largest NK Cell Therapy market with about 51% market share. Europe is follower, accounting for about 33% market share.The key manufacturers are Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech etc. Top 3 companies occupied about 82% market share.
Report Scope
Read the full market overview
This report quantifies the global NK Cell Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to NK Cell Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NK Cell Therapy Market by Company
Nektar Therapeutics
Innate Pharma SA
Affimed
Chipscreen Biosciences
Fate Therapeutics
Glycostem Therapeutics
Dragonfly Therapeutics
Kiadis Pharma
NantWorks
Nkarta Therapeutics
Fortress Biotech
NK Cell Therapy Segment by Type
NK Cell Therapies
NK Cell Directed Antibodies
NK Cell Therapy Segment by Application
Cancer
Gastrointestinal Diseases
Others
NK Cell Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of NK Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NK Cell Therapies
- NK Cell Directed Antibodies
Applications
- Cancer
- Gastrointestinal Diseases
- Others
Companies covered
- Nektar Therapeutics
- Innate Pharma SA
- Affimed
- Chipscreen Biosciences
- Fate Therapeutics
- Glycostem Therapeutics
- Dragonfly Therapeutics
- Kiadis Pharma
- NantWorks
- Nkarta Therapeutics
- Fortress Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 NK Cell Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 NK Cell Therapies
- 2.2.3 NK Cell Directed Antibodies
- 2.3 NK Cell Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Gastrointestinal Diseases
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 NK Cell Therapy Breakdown Data by Type
- 3.1 Global NK Cell Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global NK Cell Therapy Forecasted Market Size by Type (2027-2032)
4 NK Cell Therapy Breakdown Data by Application
- 4.1 Global NK Cell Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global NK Cell Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global NK Cell Therapy Market Perspective (2021-2032)
- 5.2 Global NK Cell Therapy Growth Trends by Region
- 5.2.1 Global NK Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 NK Cell Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 NK Cell Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 NK Cell Therapy Market Dynamics
- 5.3.1 NK Cell Therapy Industry Trends
- 5.3.2 NK Cell Therapy Market Drivers
- 5.3.3 NK Cell Therapy Market Challenges
- 5.3.4 NK Cell Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top NK Cell Therapy Players by Revenue
- 6.1.1 Global Top NK Cell Therapy Players by Revenue (2021-2026)
- 6.1.2 Global NK Cell Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global NK Cell Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of NK Cell Therapy Head Office and Area Served
- 6.4 Global NK Cell Therapy Players, Product Type & Application
- 6.5 Global NK Cell Therapy Manufacturers Established Date
- 6.6 Global NK Cell Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America NK Cell Therapy Market Size (2021-2032)
- 7.2 North America NK Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America NK Cell Therapy Market Size by Country (2021-2026)
- 7.4 North America NK Cell Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe NK Cell Therapy Market Size (2021-2032)
- 8.2 Europe NK Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe NK Cell Therapy Market Size by Country (2021-2026)
- 8.4 Europe NK Cell Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific NK Cell Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific NK Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific NK Cell Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific NK Cell Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America NK Cell Therapy Market Size (2021-2032)
- 10.2 South America NK Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America NK Cell Therapy Market Size by Country (2021-2026)
- 10.4 South America NK Cell Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa NK Cell Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa NK Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa NK Cell Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa NK Cell Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Nektar Therapeutics
- 12.1.1 Nektar Therapeutics Company Information
- 12.1.2 Nektar Therapeutics Business Overview
- 12.1.3 Nektar Therapeutics Revenue in NK Cell Therapy Business (2021-2026)
- 12.1.4 Nektar Therapeutics NK Cell Therapy Product Portfolio
- 12.1.5 Nektar Therapeutics Recent Developments
- 12.2 Innate Pharma SA
- 12.2.1 Innate Pharma SA Company Information
- 12.2.2 Innate Pharma SA Business Overview
- 12.2.3 Innate Pharma SA Revenue in NK Cell Therapy Business (2021-2026)
- 12.2.4 Innate Pharma SA NK Cell Therapy Product Portfolio
- 12.2.5 Innate Pharma SA Recent Developments
- 12.3 Affimed
- 12.3.1 Affimed Company Information
- 12.3.2 Affimed Business Overview
- 12.3.3 Affimed Revenue in NK Cell Therapy Business (2021-2026)
- 12.3.4 Affimed NK Cell Therapy Product Portfolio
- 12.3.5 Affimed Recent Developments
- 12.4 Chipscreen Biosciences
- 12.4.1 Chipscreen Biosciences Company Information
- 12.4.2 Chipscreen Biosciences Business Overview
- 12.4.3 Chipscreen Biosciences Revenue in NK Cell Therapy Business (2021-2026)
- 12.4.4 Chipscreen Biosciences NK Cell Therapy Product Portfolio
- 12.4.5 Chipscreen Biosciences Recent Developments
- 12.5 Fate Therapeutics
- 12.5.1 Fate Therapeutics Company Information
- 12.5.2 Fate Therapeutics Business Overview
- 12.5.3 Fate Therapeutics Revenue in NK Cell Therapy Business (2021-2026)
- 12.5.4 Fate Therapeutics NK Cell Therapy Product Portfolio
- 12.5.5 Fate Therapeutics Recent Developments
- 12.6 Glycostem Therapeutics
- 12.6.1 Glycostem Therapeutics Company Information
- 12.6.2 Glycostem Therapeutics Business Overview
- 12.6.3 Glycostem Therapeutics Revenue in NK Cell Therapy Business (2021-2026)
- 12.6.4 Glycostem Therapeutics NK Cell Therapy Product Portfolio
- 12.6.5 Glycostem Therapeutics Recent Developments
- 12.7 Dragonfly Therapeutics
- 12.7.1 Dragonfly Therapeutics Company Information
- 12.7.2 Dragonfly Therapeutics Business Overview
- 12.7.3 Dragonfly Therapeutics Revenue in NK Cell Therapy Business (2021-2026)
- 12.7.4 Dragonfly Therapeutics NK Cell Therapy Product Portfolio
- 12.7.5 Dragonfly Therapeutics Recent Developments
- 12.8 Kiadis Pharma
- 12.8.1 Kiadis Pharma Company Information
- 12.8.2 Kiadis Pharma Business Overview
- 12.8.3 Kiadis Pharma Revenue in NK Cell Therapy Business (2021-2026)
- 12.8.4 Kiadis Pharma NK Cell Therapy Product Portfolio
- 12.8.5 Kiadis Pharma Recent Developments
- 12.9 NantWorks
- 12.9.1 NantWorks Company Information
- 12.9.2 NantWorks Business Overview
- 12.9.3 NantWorks Revenue in NK Cell Therapy Business (2021-2026)
- 12.9.4 NantWorks NK Cell Therapy Product Portfolio
- 12.9.5 NantWorks Recent Developments
- 12.10 Nkarta Therapeutics
- 12.10.1 Nkarta Therapeutics Company Information
- 12.10.2 Nkarta Therapeutics Business Overview
- 12.10.3 Nkarta Therapeutics Revenue in NK Cell Therapy Business (2021-2026)
- 12.10.4 Nkarta Therapeutics NK Cell Therapy Product Portfolio
- 12.10.5 Nkarta Therapeutics Recent Developments
- 12.11 Fortress Biotech
- 12.11.1 Fortress Biotech Company Information
- 12.11.2 Fortress Biotech Business Overview
- 12.11.3 Fortress Biotech Revenue in NK Cell Therapy Business (2021-2026)
- 12.11.4 Fortress Biotech NK Cell Therapy Product Portfolio
- 12.11.5 Fortress Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst